Checkpoint Therapeutics Stock Today
| CKPT Stock | USD 4.07 0.01 0.25% |
PerformanceInsignificant
| Odds Of DistressBelow Average
|
Checkpoint Therapeutics is selling for under 4.07 as of the 22nd of March 2025; that is 0.25 percent increase since the beginning of the trading day. The stock's last reported lowest price was 4.05. Checkpoint Therapeutics has about a 41 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of June 2017 | Category Healthcare | Classification Health Care |
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. The company has 54.56 M outstanding shares of which 7.49 M shares are currently shorted by private and institutional investors with about 9.81 trading days to cover. More on Checkpoint Therapeutics
Moving against Checkpoint Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Checkpoint Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | CFA III | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsCheckpoint Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Checkpoint Therapeutics' financial leverage. It provides some insight into what part of Checkpoint Therapeutics' total assets is financed by creditors.
| |||||
Checkpoint Therapeutics (CKPT) is traded on NASDAQ Exchange in USA. It is located in 95 Sawyer Road, Waltham, MA, United States, 02453 and employs 23 people. Checkpoint Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 224.36 M. Checkpoint Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 54.56 M outstanding shares of which 7.49 M shares are currently shorted by private and institutional investors with about 9.81 trading days to cover.
Checkpoint Therapeutics currently holds about 30.89 M in cash with (47.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33.
Check Checkpoint Therapeutics Probability Of Bankruptcy
Ownership AllocationCheckpoint Therapeutics holds a total of 54.56 Million outstanding shares. 30% of Checkpoint Therapeutics outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Checkpoint Ownership Details
Checkpoint Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Wealth Enhancement Advisory Services, Llc | 2024-12-31 | 130 K | |
| Omers Administration Corp | 2024-12-31 | 116.9 K | |
| Bank Of America Corp | 2024-12-31 | 90 K | |
| Royal Bank Of Canada | 2024-12-31 | 89.9 K | |
| Legacy Wealth Asset Management, Llc | 2024-12-31 | 85 K | |
| Two Sigma Investments Llc | 2024-12-31 | 73 K | |
| Northern Trust Corp | 2024-12-31 | 72.6 K | |
| Squarepoint Ops Llc | 2024-12-31 | 71.9 K | |
| Ubs Group Ag | 2024-12-31 | 71.8 K | |
| Armistice Capital, Llc | 2024-12-31 | 4.5 M | |
| Vanguard Group Inc | 2024-12-31 | 1.9 M |
Checkpoint Therapeutics Historical Income Statement
Checkpoint Stock Against Markets
Checkpoint Therapeutics Corporate Executives
Elected by the shareholders, the Checkpoint Therapeutics' board of directors comprises two types of representatives: Checkpoint Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Checkpoint. The board's role is to monitor Checkpoint Therapeutics' management team and ensure that shareholders' interests are well served. Checkpoint Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Checkpoint Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Gray | Corporate CFO | Profile | |
| William CPA | Corporate CFO | Profile |
Additional Tools for Checkpoint Stock Analysis
When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.